SeaStar Medical vs Pulse Biosciences
ICU and PLSE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICU and PLSE compare
Pulse Biosciences is the larger company, worth 974 times as much as SeaStar Medical ($3.6B against $3.7M).
Pulse Biosciences grew revenue faster over the last twelve months (1637% versus 146% for SeaStar Medical).
SeaStar Medical keeps more of each dollar of sales as profit, with a net margin of −678% compared with −5604% at Pulse Biosciences.
Pulse Biosciences scores higher on the StockData Score (8 against 2 for SeaStar Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICU | PLSE |
|---|---|---|
| Size and price | ||
| Market cap | $3.7M | $3.6B |
| Share price | $0.838 | $50.44 |
| Change, 1 year | −83.2% | 236% |
| Change, 5 years | −100.0% | 137% |
| Beta (5Y) | 0.80 | 1.24 |
| Employees | 17 | 116 |
| StockData Score | ||
| Total score | 2 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 2408× |
| P/B | 7.9× (better) | 19.6× |
| FCF yield | – | −1.8% |
| Growth | ||
| Revenue growth (TTM) | 146% | 1637% (better) |
| Profitability | ||
| Gross margin | 92.6% (better) | 26.8% |
| Operating margin | −692% (better) | −5821% |
| Net margin | −678% (better) | −5604% |
| FCF margin | – | −4264% |
| Return on equity | −246% | −60.6% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −516.9× | – |
| Current ratio | 1.03 | 14.35 (better) |
| Altman Z-score | −51.53 | 115.81 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −93.8% | – |
| Shareholder yield | −93.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 28.1% | 15.0% |
| Held by insiders | 6.5% | 71.2% |
| Insider net buying, 12 months | $8.5K | $23.9M (better) |
| Short interest, % of float | – | 14.1% |
Go deeper
- ICU stock overview
- ICU income statement
- ICU valuation and score
- PLSE stock overview
- PLSE income statement
- PLSE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.